Q-omics provides the consensus-scored MTCO1P3 profile across patient tissues and cancer cell-line models. MTCO1P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MTCO1P3 is differentially expressed in 5, with the highest sampling consensus in PAAD. Additionally, MTCO1P3 RNA expression shows 9,357 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, PAAD, and ACC as cancer lineages where MTCO1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P3 survival associations across molecular data types. MTCO1P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P3 RNA expression–survival associations across cancer types. High MTCO1P3 expression shows unfavorable associations in CHOL and UCEC, but favorable associations in HNSC, PAAD, SKCM and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for MTCO1P3 RNA expression.
This table summarizes MTCO1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P3 shows lower tumor expression in PAAD, CHOL and LIHC and higher tumor expression in BRCA and KICH. The PAAD box plot shows higher MTCO1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.455, t-test p = .040).
This table shows molecular features associated with MTCO1P3 in patient tissues and cancer cell lines. In patient samples, MTCO1P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
